Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study

Southern Med Review

Volumn 3, Issue 1, 2010, Pages 11-18

  Othman, Noordin ^a,b   Vitry, Agnes Isabelle ^a   Roughead, Elizabeth Ellen ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Australia; Malaysia; Pharmaceutical advertisements; Promotion; Regulation

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; AUSTRALIA; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; INFORMATION PROCESSING; INTERRATER RELIABILITY; MALAYSIA; PUBLICATION; TREND STUDY; UNITED STATES;

EID: 77952755518     PISSN: None     EISSN: 11742704     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 2008; 5:3. http://www.plosmedicine.org/article/slideshow.action?uri=info:doi/10.1371/ journal.pmed.0050001&imageURI=info:doi/10.1371/journal.pmed.0050001.t001
2. Herxheimer A et al. Advertisements for Medicines in Leading Medical Journals in 18 Countries - a 12-Month Survey of Information-Content and Standards. International Journal of Health Services. 1993; 23:161-172
3. Lankinen KS et al. Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. Pharmacoepidemiology and Drug Safety. 2004; 13:789-795
4. Vlassov V et al. Do drug advertisements in Russian medical journals provide essential information for safe prescribing? Western Journal of Medicine. 2001; 174:391-394
5. Wang TJ et al. Trends in antihypertensive drug advertising, 1985-1996. Circulation. 1999; 99.
6. Hemminki E et al. The drug industry and medical practice - the case of menopausal hormone therapy in Estonia. Social Science & Medicine. 2004; 58:89-97.
7. World Health Organization. Ethical criteria for medical drug promotion. http://www.who.int/medicinedocs (Accessed 3 Aug. 2009).
8. International Federation of Pharmaceutical Manufacturers Associations (IFPMA). Code of Pharmaceutical Marketing. http://www.ifpma.org/pdf/IFPMA- TheCode-FinalVersion-30May2006-EN.pdf (Accessed 3 Sep. 2009).
9. Morris LA, Pines WL. Regulation of pharmaceutical promotion in the twenty-first century. Drug Information Journal. 2000; 34:861-873
10. The Organisation for Professionals in Regulatory Affairs. Worldwide survey on national controls of pharmaceutical advertising and promotion http://www.topra.org/files/2005N11-Focus-02.pdf (Accessed 11 Mar. 2009).
11. Medicines Australia. Code of Conduct Edition 14. http://www. medicinesaustralia.com.au/pages/page58.asp (15 Aug. 2008).
12. Pharmaceutical Associations of Malaysia. Code of conduct for prescription (ethical) products. http://www.phama.org.my/ (Accessed 22 Dec. 2008 ).
13. Roughead EE. The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines. Aust Prescr 1990; 152:57-59
14. Pharmacy Service Division. Medicine Advertisement Board, Ministry of Health Malaysia. http://www.pharmacy.gov.my/html/MAB/advertisement-board-f.htm (Accessed 22 Dec. 2008).
15. U.S. Food and Drug Administration, Center of Drug Evaluation and Research Handbook. http://www.fda.gov/cder/handbook/ (Accessed 21 Aug. 2009).
16. U.S. Food and Drug Administration. Prescription Drug Advertising: Questions and Answers. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ PrescriptionDrugAdvertising/UCM076768.htm (Accessed 22 Feb. 2009).
17. Wyeth. Wyeth Code of Conduct. http://phx.corporate-ir.net/phoenix.zhtml? c=78193&p=irol-govconduct (Accessed 3 Dec. 2008).
18. The Principles of Good Promotional Practices at Sanofi-Aventis. Sanofi-Aventis. http://sustainability.sanofi-aventis.com/societal/mark-resp/ promotion-etat.asp (Accessed 3 Oct. 2008).
19. Norvatis. The Novartis Pharma Promotional Practices Policy. http://www.corporatecitizenship.novartis.com/downloads/business-conduct/ NP4-Policy-revised-2004.pdf (Accessed 3 Oct. 2008)
20. Othman N et al. Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review. PLoS ONE. 2009; 4:e6350.
21. Wilkes MS et al. Pharmaceutical Advertisements in Leading Medical Journals - Experts Assessments. Annals of Internal Medicine. 1992; 116:912-919
22. Carandang ED, Moulds RFW. Pharmaceutical Advertisements in Australian Medical Publications - Have They Improved. Medical Journal of Australia. 1994; 161.
23. Russell Johns Associates. American Family Physician. http://search.rja- ads.com/action.lasso?-Database=rja-mags&-Layout=web&-Response=magazines. lasso&-AnyError=search-error.lasso&magazineID=af&-search (Accessed 8 Feb. 2009 ).
24. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. 2005; 37:360-363
25. Lal A et al. Comparative evaluation of drug advertisements in Indian, British and American medical journals. Journal of the Indian Medical Association. 1997; 95:19-20.
26. Gitanjali B et al. Are drug advertisements in Indian edition of BMJ unethical? BMJ. 1997; 315.
27. Raj ST. Doctors and drug companies: End these unethical practices. http://www.nst.com.my/Current-News/nst/Thursday/Letters/20070329084438/Article/ index-html (Accessed 19 Apr 2007).
28. Medicines Australia. Code of Conduct Annual Reports. http://www. medicinesaustralia.com.au/pages/page30.asp (Accessed 15 Aug. 2008).
29. Lexchin J. Enforcement of codes governing pharmaceutical promotion: What happens when companies breach advertising guidelines? Canadian Medical Association Journal. 1997; 156.
30. General Accounting Office. Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. http://www.gao.gov/new.items/ d03177.pdf (Accessed 3 Feb. 2009).
31. Anderson BL et al. Factors associated with physicians' reliance on pharmaceutical sales representatives. Academic Medicine. 2009; 84:994-1002.
32. AstraZeneca. Global Code of Conduct. https://secure.ethicspoint.com/ domain/media/en/gui/20849/CodeOfConduct.pdf (Accessed 3 Oct. 2008).
33. Pfizer. Global Policy on Interactions with Healthcare Professionals. http://media.pfizer.com/files/corporate-citizenship/global-policy-interactions- hcps.pdf (Accessed 3 Oct. 2008).
34. Schering-Plough. Standards of Global Business Practices. http://www.schering-plough.com./binaries/ Standards%20of%20Global%20Business%20Practices-tcm137-166597.pdf (Accessed 3 Dec. 2008).
35. Merck. The Merck Code of Conduct. http://www.merck.com/about/code-of- conduct.pdf (Accessed 3 Dec. 2008).
36. Lexchin J. Deception by design Pharmaceutical promotion in the Third World. Penang: Consumers International; 1996.